Sino Biopharmaceutical Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

May 04, 2025

Sino Biopharmaceutical (HKG:1177) Full Year 2024 Results

Key Financial Results

Revenue: CN¥28.9b (up 10% from FY 2023).
Net income: CN¥1.92b (up 3.9% from FY 2023).
Profit margin: 6.7% (down from 7.1% in FY 2023).
EPS: CN¥0.10 (up from CN¥0.10 in FY 2023).

Our free stock report includes 1 warning sign investors should be aware of before investing in Sino Biopharmaceutical. Read for free now.

1177 Post-Clinical Trial Products

Approved (during full year): 1.

revenue-and-expenses-breakdown — SEHK:1177 Revenue and Expenses Breakdown May 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sino Biopharmaceutical EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 3.7%.

The primary driver behind last 12 months revenue was the Modernised Chinese Medicines and Chemical Medicines segment contributing a total revenue of CN¥28.5b (99% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥10.1b (47% of total expenses). Explore how 1177's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Sino Biopharmaceutical is showing 1 warning sign in our investment analysis that you should know about...

If you're looking to trade Sino Biopharmaceutical, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.